Cardiogenic Shock Working Group Registry
ConditionCardiogenic Shock
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorTufts Medical Center
About this trial
The Cardiogenic Shock Working Group is a multicenter registry where we collect de-identified clinical variables from the medical records and follow-up phone calls of shock patients from multiple institutions and centralize this data to a single registry for analysis of clinical outcomes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients must have cardiogenic shock.
Cardiac Index < 2.2
PAPI < 1.0
Cardiac Power Output ≤ 0.6
Disqualifiers
None
Trial population
People who are 18 or older who have an official diagnosis of cardiogenic shock.
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Vasopressor
DrugThe vasopressors include phenylephrine, norepinephrine, epinephrine, dopamine and vasopressin.
Inotrope
DrugInotropes include dobutamine and milrinone.
Acute Mechanical Circulatory Support Devices
DeviceAcute Mechanical Circulatory Support devices include ECMO (VV), ECMO (VA), Impella CP, Impella 2.5, Impella 5.0, Impella 5.5, Impella RP, IABP, Centrimag, Tandem Heart and ProTek Duo.
Treatment groups
5,000 Participants
are divided into 1 treatment groupGroup A: Cardiogenic Shock Patients3 interventions
Trial outcomes
Primary outcomes
1
Rate of Mortality
Death in subjects during the time frame.
Time frame
30 days after discharge2
Rate of Mortality
Death in subjects during the time frame.
Time frame
1 year after dischargeSecondary outcomes
1
Rate of Re-hospitalization
We will be observing if patient was hospitalized again during the 1 year-time frame. We will collect information on surgeries and interventions during the course of rehospitalization.
Time frame
30 day after discharge2
Rate of Re-hospitalization
We will be observing if patient was hospitalized again during the 1 year-time frame. We will collect information on surgeries and interventions during the course of rehospitalization.
Time frame
1 year after discharge3
New York Heart Association (NYHA) Class
NYHA Classification provides a way to classify the stages of heart failure. Class I- No symptoms and no limitation in ordinary physical activity Class II- Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity Class IV - Severe limitations
Time frame
30 day after discharge4
New York Heart Association (NYHA) Class
NYHA Classification provides a way to classify the stages of heart failure. Class I- No symptoms and no limitation in ordinary physical activity Class II- Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity Class IV - Severe limitations
Time frame
1 year after dischargeSponsors and contacts
Click on the lead sponsor to view all of their trials.
Tufts Medical Center
Lead sponsor
Abbott
Collaborator
Boston Scientific Corporation
Collaborator
Abiomed Inc.
Collaborator
Getinge Group
Collaborator
Source ClinicalTrials.gov